Related Experiment Video

Updated: Jun 20, 2026

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

Serum prohepcidin levels correlate with hepatic iron stores in chronic hepatitis C patients

Tsung-Jung Lin1, Li-Ying Liao, Jung-Mao Chou

  • 1Department of Gastroenterology, Ren-Ai Branch, Taipei City Hospital, Taipei, Taiwan.

Hepato-Gastroenterology
|September 19, 2009
PubMed

Insights

Serum prohepcidin levels are elevated in chronic hepatitis C patients, correlating with hepatic iron stores but not inflammation. This suggests increased hepatic iron may induce hepcidin expression in CHC.

Area of Science:

  • Hepatology
  • Iron Metabolism
  • Biochemistry

Background:

  • Chronic hepatitis C (CHC) often presents with elevated serum iron and hepatic iron.
  • Hepcidin, an antimicrobial peptide produced by the liver, is crucial for regulating iron homeostasis.

Purpose of the Study:

  • To investigate hepcidin expression in patients with chronic hepatitis C.
  • To determine the relationship between serum prohepcidin levels, hepatic iron stores, and inflammation markers in CHC.

Main Methods:

  • Serum prohepcidin levels were quantified in 58 CHC patients and 144 healthy controls.
  • Hepatic iron stores were assessed using Perls' stain on liver biopsy specimens.
  • Correlations were analyzed between serum prohepcidin and various clinical, biochemical, and histological parameters.

Main Results:

  • Serum prohepcidin concentrations were significantly higher in CHC patients compared to controls (142.07 vs. 89.07 ng/mL).
  • CHC patients with positive hepatic iron stains exhibited significantly higher serum prohepcidin levels (221.20 vs. 123.81 ng/mL).
  • No significant correlations were found between serum prohepcidin and age, hemoglobin, ALT, transferrin saturation, ferritin, or hepatic inflammation grades.

Conclusions:

  • Serum prohepcidin levels are elevated in CHC patients and associated with hepatic iron deposition.
  • Hepcidin expression in CHC appears independent of the degree of hepatic inflammation.
  • Increased hepatic iron stores may be a key factor inducing hepcidin expression in CHC.
Abstract

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice08:32

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice

Published on: March 10, 2017

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...